{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=21", "query": { "condition": "Relapse/Recurrence", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 3147, "total_pages": 315, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T10:58:17.548Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00967044", "title": "Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2009-11", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-02-26", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00967044" }, { "nct_id": "NCT00698516", "title": "Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Small-cell Lung Cancer (SCLC)", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2008-07", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-03-27", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 16, "location_summary": "Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698516" }, { "nct_id": "NCT04939272", "title": "Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-06-29", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04939272" }, { "nct_id": "NCT00003281", "title": "Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "1998-04", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003281" }, { "nct_id": "NCT01349881", "title": "S0820, Adenoma and Second Primary Prevention Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Eflornithine placebo & sulindac placebo", "type": "DRUG" }, { "name": "eflornithine & sulindac placebo", "type": "DRUG" }, { "name": "Eflornithine placebo & sulindac", "type": "DRUG" }, { "name": "Eflornithine plus sulindac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 354, "start_date": "2013-08-23", "completion_date": "2032-02-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 989, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349881" }, { "nct_id": "NCT00695409", "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "ASCT", "type": "PROCEDURE" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2008-03-18", "completion_date": "2017-03-27", "has_results": true, "last_update_posted_date": "2018-07-06", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00695409" }, { "nct_id": "NCT01852292", "title": "Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Buparlisib", "type": "DRUG" }, { "name": "Buparlisib matching Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2013-10-01", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 7, "location_summary": "Fayetteville, Arkansas • Boston, Massachusetts • St Louis, Missouri + 4 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01852292" }, { "nct_id": "NCT02499328", "title": "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "AZD9150", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "AZD5069", "type": "DRUG" }, { "name": "tremelimumab (treme)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 340, "start_date": "2015-08-06", "completion_date": "2025-10-08", "has_results": true, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02499328" }, { "nct_id": "NCT05154487", "title": "A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometroid Endometrial Cancer" ], "interventions": [ { "name": "Alpelisib Pill", "type": "DRUG" }, { "name": "Fulvestrant injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2024-09-11", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 21, "location_summary": "Duarte, California • Miami Beach, Florida • Orlando, Florida + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05154487" }, { "nct_id": "NCT04081259", "title": "LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-07-15", "completion_date": "2023-08-26", "has_results": false, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-11-04T10:58:17.548Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081259" } ] }